Phenylketonuria Scientific Review Conference: State of the science and future research needs

• Published in: Molecular genetics and metabolism Vol. 112; no. 2; pp. 87 - 122
• Main Authors: Camp, Kathryn M., Parisi, Melissa A., Acosta, Phyllis B., Berry, Gerard T., Bilder, Deborah A., Blau, Nenad, Bodamer, Olaf A., Brosco, Jeffrey P., Brown, Christine S., Burlina, Alberto B., Burton, Barbara K., Chang, Christine S., Coates, Paul M., Cunningham, Amy C., Dobrowolski, Steven F., Ferguson, John H., Franklin, Thomas D., Frazier, Dianne M., Grange, Dorothy K., Greene, Carol L., Groft, Stephen C., Harding, Cary O., Howell, R. Rodney, Huntington, Kathleen L., Hyatt-Knorr, Henrietta D., Jevaji, Indira P., Levy, Harvey L., Lichter-Konecki, Uta, Lindegren, Mary Lou, Lloyd-Puryear, Michele A., Matalon, Kimberlee, MacDonald, Anita, McPheeters, Melissa L., Mitchell, John J., Mofidi, Shideh, Moseley, Kathryn D., Mueller, Christine M., Mulberg, Andrew E., Nerurkar, Lata S., Ogata, Beth N., Pariser, Anne R., Prasad, Suyash, Pridjian, Gabriella, Rasmussen, Sonja A., Reddy, Uma M., Rohr, Frances J., Singh, Rani H., Sirrs, Sandra M., Stremer, Stephanie E., Tagle, Danilo A., Thompson, Susan M., Urv, Tiina K., Utz, Jeanine R., van Spronsen, Francjan, Vockley, Jerry, Waisbren, Susan E., Weglicki, Linda S., White, Desirée A., Whitley, Chester B., Wilfond, Benjamin S., Yannicelli, Steven, Young, Justin M.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: United States Elsevier Inc 01.06.2014
• Subjects: Biopterins - analogs & derivatives; Biopterins - therapeutic use; Diet Therapy; Disease Management; Evidence-Based Medicine; Female; Glycomacropeptide; Humans; Hyperphenylalaninemia; Infant, Newborn; Large neutral amino acids; Maternal PKU; National Institutes of Health (U.S.); Phenylketonuria; Phenylketonurias - blood; Phenylketonurias - diagnosis; Phenylketonurias - therapy; Practice Guidelines as Topic; Pregnancy; Sapropterin; United States; LNAA; FDA; MPKUS; CDE; MRI; Large neutral amino acids; RUSP; CNS; NICHD; GMDI; SIMD; Phe; COA; ORDR; BMD; ODS; Sapropterin; ACMG; PKUDOS; Phenylketonuria; DHPR; IQ; NDSI; SOE; GMP; DXA; NIH; Tyr; BH4; Hyperphenylalaninemia; IEM; NBSTRN; PEG; Glycomacropeptide; AAV; MPKCUS; PAH; AHRQ; HPA; EPC; DRI; PAL; START; PKU; DHA; CHD; Maternal PKU
• ISSN: 1096-7192; 1096-7206
• DOI: 10.1016/j.ymgme.2014.02.013

New developments in the treatment and management of phenylketonuria (PKU) as well as advances in molecular testing have emerged since the National Institutes of Health 2000 PKU Consensus Statement was released. An NIH State-of-the-Science Conference was convened in 2012 to address new findings, particularly the use of the medication sapropterin to treat some individuals with PKU, and to develop a research agenda. Prior to the 2012 conference, five working groups of experts and public members met over a 1-year period. The working groups addressed the following: long-term outcomes and management across the lifespan; PKU and pregnancy; diet control and management; pharmacologic interventions; and molecular testing, new technologies, and epidemiologic considerations. In a parallel and independent activity, an Evidence-based Practice Center supported by the Agency for Healthcare Research and Quality conducted a systematic review of adjuvant treatments for PKU; its conclusions were presented at the conference. The conference included the findings of the working groups, panel discussions from industry and international perspectives, and presentations on topics such as emerging treatments for PKU, transitioning to adult care, and the U.S. Food and Drug Administration regulatory perspective. Over 85 experts participated in the conference through information gathering and/or as presenters during the conference, and they reached several important conclusions. The most serious neurological impairments in PKU are preventable with current dietary treatment approaches. However, a variety of more subtle physical, cognitive, and behavioral consequences of even well-controlled PKU are now recognized. The best outcomes in maternal PKU occur when blood phenylalanine (Phe) concentrations are maintained between 120 and 360μmol/L before and during pregnancy. The dietary management treatment goal for individuals with PKU is a blood Phe concentration between 120 and 360μmol/L. The use of genotype information in the newborn period may yield valuable insights about the severity of the condition for infants diagnosed before maximal Phe levels are achieved. While emerging and established genotype–phenotype correlations may transform our understanding of PKU, establishing correlations with intellectual outcomes is more challenging. Regarding the use of sapropterin in PKU, there are significant gaps in predicting response to treatment; at least half of those with PKU will have either minimal or no response. A coordinated approach to PKU treatment improves long-term outcomes for those with PKU and facilitates the conduct of research to improve diagnosis and treatment. New drugs that are safe, efficacious, and impact a larger proportion of individuals with PKU are needed. However, it is imperative that treatment guidelines and the decision processes for determining access to treatments be tied to a solid evidence base with rigorous standards for robust and consistent data collection. The process that preceded the PKU State-of-the-Science Conference, the conference itself, and the identification of a research agenda have facilitated the development of clinical practice guidelines by professional organizations and serve as a model for other inborn errors of metabolism. •NIH convened work groups and a conference to address research and treatment for PKU.•Sapropterin may allow liberalization of a Phe-restricted diet for those who respond.•New therapies are needed to optimize quality of life across the lifespan.•Research is needed on strategies to improve access to and compliance with treatment.•Management guidelines must be based on rigorous study design and outcome measures.